Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

The calming in the oil market came as several analysts said Iran would likely refrain from closing the waterway. Iran itself ...

U.S. stocks are drifting, and oil prices are flip-flopping following the United States’ bunker-busting entry into Israel’s ...

Jeffrey Ettinger is returning to Hormel Foods to serve as its interim chief executive for 15 months, effective July 14. Chief Executive Antonio Filosa shuffled responsibilities within the Jeep parent ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Shares of Hims & Hers Health plunged by more than 30% after Danish weight-control drug maker Novo Nordisk abruptly pulled out of a partnership with the telehealth firm on the distribution of Wegovy.

Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.